摘要
Abstract
Objective To study the effect of ulinastatin combined with Linezolid on inflammatory reaction and lung function indicators in patients with severe pneumonia.Methods 96 patients with severe pneumonia were selected and divided into two groups according to different treatment methods,with 48 cases in each group.The control group was treated with Linezolid,and the observation group was treated with ulinastatin combined with Linezolid for 4 weeks.Compare the clinical ef-ficacy,inflammation levels,lung function,and adverse reactions between the two groups.The total effective rate of the observa-tion group was 95.83%(46/48),which was statistically significant(P＜0.05)compared to 83.33%(40/48)of the control group;Af-ter treatment,in the observation group,the level of Calcitonin(PCT)was(340.57±57.34)ng/L,the level of C-reactive protein(CRP)was(10.02±3.21)mg/L,and tumor necrosis factor(TNF-α)The level was(10.87±8.21)pg/mL,lower than the control group's(510.36±62.37)ng/L,(25.69±5.31)mg/L,and(19.45±8.10)pg/mL;The index of forced expiratory volume(FEV1)in 1s was(50.02±0.25)%,the index of forced Vital capacity(FVC)was(67.38±8.97)%,and the index of maximum expiratory peak flow rate(PEF)was(2.05±0.35)L·s-1,which was higher than that of the control group(45.31±1.15)%,(59.57±7.66)%,(1.54±0.27)L·s-1,with statistical significance(P＜0.05);There was no statistically significant difference in adverse reactions between the two groups(P＞0.05).Conclusion The combination of Linezolid and ulinastatin can effectively alleviate the clinical symptoms,improve the lung function,reduce the inflammatory reaction in patients with severe pneumonia,and improve the clinical effi-cacy,which is safe and reliable.关键词
重症肺炎患者/乌司他丁/利奈唑胺/炎症/肺功能Key words
Patients with severe pneumonia/Ulinastatin/Linezolid/Inflammation/Pulmonary functio分类
医药卫生
